IsoRay completes merger with Viewpoint Molecular Targeting

By staff writers

February 6, 2023 -- Medical isotope developer IsoRay has completed its merger with Viewpoint Molecular Targeting. The deal closed on February 3.

The two firms plan to focus on developing targeted cancer treatment using radiation, radiopharmaceuticals, and imaging. Viewpoint Molecular chief executive officer Thijs Spoor will be CEO of the newly combined company, while outgoing IsoRay CEO Lori Woods has been named chair of the board of directors.

Copyright © 2023

To read this and get access to all of the exclusive content on create a free account or sign-in now.

Member Sign In:
MemberID or Email Address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking